NCT07841093Not yet recruitingPhase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of JMKX003142 Tablet in the Treatment of Renal Edema
Jemincare1 site in 1 country240 target enrollmentStarted: February 28, 2027Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- Change of body weight from baseline
Study Overview
Brief Summary
To evaluate the efficacy, safety, and of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic therapy.
Detailed Description
JMKX003142 is an arginine vasopressin（AVP）-V2R antagonist which shows a remarkable diuretic effect in healthy volunteers（phase 1 study） and renal edema patients（phase 2 study）.In this phase 3 study ，we will observe the safety 、efficacy about JMKX003142 tablet in renal edema who have an inadequate response to conventional diuretic therapy. This phase 3 study is designed as a randomly, double-blind,placebo-controlled study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who can fully understand the purpose and process of the study and voluntarily sign the informed consent form（ICF）;
- •Age ≥ 18 years old during screening;
- •Diagnosed as renal edema during screening;
- •Estimated glomerular filtration rate（eGFR） ≥ 15 mL/min/1.73m2 during screening.
- •At the start of the run-in period,patients must have been receiving either a loop diuretic at a dose equivalent to ≥40 mg of furosemide or a combination of any dose of a loop diuretic with a diuretic of another class (different mechanism of action) as the background therapy medication.
- •Body weight change of <1.0 kg during the run-in period.No changes in the conventional diuretic regimen during the run-in period.
Exclusion Criteria
- •Patients who are receiving the renal replacement therapy during screening or patients who require renal replacement therapy in the short term evaluated by the researchers;
- •Patients who are suspected with hypovolemia;
- •Patients with the following diseases or symptoms: acute thrombosis, diarrhea, and difficulty urinating;
- •Patients who are unable to sense thirst or who have difficulty with fluid intake;
- •Patients who have received arginine vasopressin-V2R blockers within 14 days prior to the randomization;
- •The following laboratory indicators are abnormal: glutamic pyruvic transaminase ≥ 1.5 ×upper limit of normal, glutamic oxaloacetic transaminase ≥ 1.5 × upper limit of normal, serum sodium> upper limit of normal;
- •Patients who received diuretics or treatments with diuretic effects（except for the background therapy medication） from Day-3 to randomization;
- •During screening, systolic blood pressure <90 mmHg;
- •Patients who have a history of allergies to ≥ 3 substances, or are currently in an allergic state;
- •Female patients who are breast-feeding or who have a positive pregnancy test result prior to receiving investigational product (IMP);
- •Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice birth control or remain abstinent during the trial and for 30 days after the final IMP administration.
Arms & Interventions
JMKX003142 tablet group
Experimental
take orally once daily，last for 7 days
Intervention: JMKX003142 Tablets (Drug)
placebo group
Placebo Comparator
take orally once daily，last for 7 days
Intervention: Placebo Tablets (Drug)
Outcomes
Primary Outcomes
Change of body weight from baseline
Time Frame: Day 8
Secondary Outcomes
- Change of body weight from baseline(Day 2 to day 7)
- Daily urine volume(Day 2 to day 7)
- Daily fluid balance(Day 1 to Day 7)
- Resolution rate of lower limb edema(Day 2 to day 8)
- Incidence rate of adverse events(From the first dose through 7 days after the last dose)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderDepressive Disorder, MajorNCT07573176Janssen Research & Development, LLC600
Not yet recruiting
Phase 3
JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast CancerBreast CancerNCT07784036Chengdu JOYO pharma Co., Ltd.171
Recruiting
Phase 3
A Study of DA-302168S in Participants With Overweight/ObesityOverweight and ObesityNCT07629544Chendu DIAO Pharmaceutical Group CO., LTD.840
Not yet recruiting
Phase 3
1% Clascoterone Cream for the Treatment Acne VulgarisAcne VulgarisNCT07457294Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.692
Recruiting
Phase 3
Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisSeasonal Allergic Rhinitis (SAR)NCT07678931Chengdu Kangnuoxing Biopharma,Inc.136